Michael Gross is managing director of Beringea. He is responsible for investment sourcing, deal execution and portfolio management, with a focus on healthcare, technology enabled services, and sustainability. Michael serves as a board director for Beringea portfolio companies MI Bioresearch, D3O, Delphinus Medical Technologies, InTouch Health, Intervention Insights, Xanitos, Freeosk, Rethink and Fiber By-Products. Previous portfolio companies include Pioneer Surgical Technologies (acquired by RTI Biologics), Relume Technologies (acquired by Revolution Lighting), and EcoSynthetix (offered publicly at TSX: ECO).
Prior to joining Beringea, Michael was a vice president of investment banking with P&M Corporate Finance (PMCF). While at PMCF, Michael led M&A transactions and capital raises for companies in the life sciences, health care and outsourced business services sectors. Before working at PMCF, Michael worked in the investment banking group at Stout Risius Ross, Inc.
Michael is a CFA charterholder and earned a Bachelor of Arts in finance from Michigan State University.